Commvault Systems Inc vs Smith & Nephew plc — how do they compare? Commvault Systems Inc trades at $151.43 (market cap $6.25B), while Smith & Nephew plc trades at $27.32 (market cap $11.10B). The key difference: Smith & Nephew plc is the larger of the two by market cap, and Smith & Nephew plc pays a 2.95% dividend while Commvault Systems Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Commvault Systems Inc for 17 Days and Smith & Nephew plc for 120 Days on average.
| CVLT | SNN | |
|---|---|---|
Market Cap | $6.25B | $11.10B |
Volume | 632,727 | 1,051,703 |
Sector | Technology | Health |
52-Week High | $176.52 | $37.17 |
52-Week Low | $75.18 | $26.42 |
Typical Hold Time | 17 Days | 120 Days |
Enterprise Value | $6.24B | $14.13B |
Dividend Yield | — | 2.95% |
Signals from Pluang's Aura AI — not financial advice
Commvault Systems (CVLT) trades at $150.28, down 3.03% on the day, but maintains a bullish technical outlook with strong institutional support. The company shows robust earnings momentum with three consecutive quarterly beats and impressive profitability metrics including 81.09% gross margins and 32.77% ROE. Recent business developments include achieving AWS Data Competency and expanding FedRAMP High authorized services, positioning the company for continued growth in the cybersecurity resilience market.
CVLT presents a compelling growth story with strong fundamentals and positive analyst sentiment, though elevated valuation ratios (P/E 96.73, P/B 120.15) suggest premium pricing. The primary investment opportunity lies in the company's leadership in AI-era resilience solutions, while risks include valuation sensitivity and competitive pressures in the enterprise software space. Wall Street maintains a bullish stance with 54.55% buy ratings and a $156.55 consensus price target.
SNN trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue and net income have grown steadily, reaching $6.16B and $625M in 2025, respectively, with improving margins. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. However, cash flow volatility and mixed analyst sentiment pose challenges.
The stock presents a value opportunity with reasonable valuation ratios (P/E 18.34, P/S 1.85), but risks include competitive pressures and recent CFO departure. Analyst consensus is cautious, with 65% hold ratings. Upside depends on execution of growth initiatives amid market headwinds.
Trailing returns across standard periods
Latest headlines on both assets
Commvault provides enterprise-grade data protection and information management software. Its platform helps businesses manage, back up, and recover data across on-premises, cloud, and hybrid environments.
Read more on CVLT →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →